Literature DB >> 30421146

Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study.

Philip M Jones1,2,3, Britney N Allen4, Richard A Cherry5, Luc Dubois6, Kelly N Vogt7,6, Salimah Z Shariff4,8, Krista M Bray Jenkyn4, Sheila Riazi9,10, Duminda N Wijeysundera9,10,11,12,13.   

Abstract

PURPOSE: Whether current standards of care management for malignant hyperthermia (MH)-susceptible patients result in acceptable postoperative clinical outcomes at a population level is not known. Our objective was to determine if patients with susceptibility to MH experienced similar outcomes as patients without MH susceptibility after surgery under general anesthesia.
METHODS: This was a retrospective, population-based cohort study from 1 April 2009 until 31 March 2016 in the Canadian province of Ontario. Participants were adults who underwent common in- or outpatient surgeries under general anesthesia. The exposure studied was either known or strongly suspected MH susceptibility as determined by usage of a specific physician billing code. The primary outcome was a composite of all-cause death, hospital readmission, or major postoperative complications, all within 30 postoperative days. Separate analyses were employed, based on whether a patient had in- or outpatient surgery. Inverse probability of exposure weighting based on the propensity score was used to estimate adjusted exposure effects.
RESULTS: The cohort included 957,876 patients (583,254 in- and 374,622 outpatients). There were 2,900 (0.3%) patients with a known or strong suspicion of MH susceptibility. For inpatients, the primary outcome occurred in 146,192 (25.1%) of the non-MH-susceptible group and in 337 (20.1%) of the MH-susceptible group (unadjusted risk difference [RD], -5.0%; 95% confidence interval [CI], -6.9 to -3.1%; P < 0.001). In outpatients, the primary outcome occurred in 9,146 (2.4%) of the non-MH-susceptible group and in 32 (2.6%) of the MH-susceptible group (RD, 0.2%; 95% CI, -0.7 to 1.1%; P = 0.72). After adjustment, MH susceptibility was not associated with the primary outcome in either the inpatients (adjusted risk difference [aRD], 1.2%; 95% CI, -1.3 to 3.6%; P = 0.35) or outpatients (aRD, -0.1%; 95% CI -1.0 to 0.9%; P = 0.90).
CONCLUSIONS: Among adults in Ontario who underwent common surgeries under general anesthesia from 2009 to 2016, known or strongly suspected MH was not associated with a higher risk of adverse postoperative outcomes. These findings support the current standard of care management for MH-susceptible patients.

Entities:  

Mesh:

Year:  2018        PMID: 30421146     DOI: 10.1007/s12630-018-1250-8

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  18 in total

1.  Idiopathic hyperCKemia and malignant hyperthermia susceptibility.

Authors:  Joilson M Santos; Pamela V Andrade; Leonardo Galleni; Mariz Vainzof; Claudia F R Sobreira; Beny Schmidt; Acary S B Oliveira; José L G Amaral; Helga C A Silva
Journal:  Can J Anaesth       Date:  2017-09-26       Impact factor: 5.063

Review 2.  Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum.

Authors:  David H Maclennan; Elena Zvaritch
Journal:  Biochim Biophys Acta       Date:  2010-11-27

Review 3.  Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.

Authors:  Natalia Kraeva; Alexander Sapa; James J Dowling; Sheila Riazi
Journal:  Can J Anaesth       Date:  2017-03-21       Impact factor: 5.063

4.  Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.

Authors:  Marilyn Green Larach; Gerald A Gronert; Gregory C Allen; Barbara W Brandom; Erik B Lehman
Journal:  Anesth Analg       Date:  2010-02-01       Impact factor: 5.108

Review 5.  Updated guide for the management of malignant hyperthermia.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Can J Anaesth       Date:  2018-03-29       Impact factor: 5.063

6.  Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.

Authors:  Sheila Riazi; Marilyn Green Larach; Charles Hu; Duminda Wijeysundera; Christine Massey; Natalia Kraeva
Journal:  Anesth Analg       Date:  2014-02       Impact factor: 5.108

Review 7.  Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients.

Authors:  Barbara W Brandom; Sheila M Muldoon
Journal:  Paediatr Anaesth       Date:  2013-07-15       Impact factor: 2.556

8.  Deriving ICD-10 Codes for Patient Safety Indicators for Large-scale Surveillance Using Administrative Hospital Data.

Authors:  Danielle A Southern; Bernard Burnand; Saskia E Droesler; Ward Flemons; Alan J Forster; Yana Gurevich; James Harrison; Hude Quan; Harold A Pincus; Patrick S Romano; Vijaya Sundararajan; Nenad Kostanjsek; William A Ghali
Journal:  Med Care       Date:  2017-03       Impact factor: 2.983

Review 9.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Authors:  Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

10.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan
Journal:  PLoS Med       Date:  2015-10-06       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.